These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

356 related articles for article (PubMed ID: 36623243)

  • 1. Contralateral Breast Cancer Risk Among Carriers of Germline Pathogenic Variants in
    Yadav S; Boddicker NJ; Na J; Polley EC; Hu C; Hart SN; Gnanaolivu RD; Larson N; Holtegaard S; Huang H; Dunn CA; Teras LR; Patel AV; Lacey JV; Neuhausen SL; Martinez E; Haiman C; Chen F; Ruddy KJ; Olson JE; John EM; Kurian AW; Sandler DP; O'Brien KM; Taylor JA; Weinberg CR; Anton-Culver H; Ziogas A; Zirpoli G; Goldgar DE; Palmer JR; Domchek SM; Weitzel JN; Nathanson KL; Kraft P; Couch FJ
    J Clin Oncol; 2023 Mar; 41(9):1703-1713. PubMed ID: 36623243
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Association of a Polygenic Risk Score With Breast Cancer Among Women Carriers of High- and Moderate-Risk Breast Cancer Genes.
    Gallagher S; Hughes E; Wagner S; Tshiaba P; Rosenthal E; Roa BB; Kurian AW; Domchek SM; Garber J; Lancaster J; Weitzel JN; Gutin A; Lanchbury JS; Robson M
    JAMA Netw Open; 2020 Jul; 3(7):e208501. PubMed ID: 32609350
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Cancer risk management among female BRCA1/2, PALB2, CHEK2, and ATM carriers.
    Cragun D; Weidner A; Tezak A; Clouse K; Pal T
    Breast Cancer Res Treat; 2020 Jul; 182(2):421-428. PubMed ID: 32445176
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Risk of Late-Onset Breast Cancer in Genetically Predisposed Women.
    Boddicker NJ; Hu C; Weitzel JN; Kraft P; Nathanson KL; Goldgar DE; Na J; Huang H; Gnanaolivu RD; Larson N; Yussuf A; Yao S; Vachon CM; Trentham-Dietz A; Teras L; Taylor JA; Scott CE; Sandler DP; Pesaran T; Patel AV; Palmer JR; Ong IM; Olson JE; O'Brien K; Neuhausen S; Martinez E; Ma H; Lindstrom S; Le Marchand L; Kooperberg C; Karam R; Hunter DJ; Hodge JM; Haiman C; Gaudet MM; Gao C; LaDuca H; Lacey JV; Dolinsky JS; Chao E; Carter BD; Burnside ES; Bertrand KA; Bernstein L; Auer PW; Ambrosone C; Yadav S; Hart SN; Polley EC; Domchek SM; Couch FJ
    J Clin Oncol; 2021 Nov; 39(31):3430-3440. PubMed ID: 34292776
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Pathogenic and likely pathogenic variants in PALB2, CHEK2, and other known breast cancer susceptibility genes among 1054 BRCA-negative Hispanics with breast cancer.
    Weitzel JN; Neuhausen SL; Adamson A; Tao S; Ricker C; Maoz A; Rosenblatt M; Nehoray B; Sand S; Steele L; Unzeitig G; Feldman N; Blanco AM; Hu D; Huntsman S; Castillo D; Haiman C; Slavin T; Ziv E
    Cancer; 2019 Aug; 125(16):2829-2836. PubMed ID: 31206626
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Germline testing of
    Woodward ER; Lalloo F; Forde C; Pugh S; Burghel GJ; Schlecht H; Harkness EF; Howell A; Howell SJ; Gandhi A; Evans DG
    J Med Genet; 2024 Mar; 61(4):385-391. PubMed ID: 38123987
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Radiation Treatment, ATM, BRCA1/2, and CHEK2*1100delC Pathogenic Variants and Risk of Contralateral Breast Cancer.
    Reiner AS; Robson ME; Mellemkjær L; Tischkowitz M; John EM; Lynch CF; Brooks JD; Boice JD; Knight JA; Teraoka SN; Liang X; Woods M; Shen R; Shore RE; Stram DO; Thomas DC; Malone KE; Bernstein L; Riaz N; Woodward W; Powell S; Goldgar D; Concannon P; ; Bernstein JL
    J Natl Cancer Inst; 2020 Dec; 112(12):1275-1279. PubMed ID: 32119081
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Predicted Chemotherapy Benefit for Breast Cancer Patients With Germline Pathogenic Variants in Cancer Susceptibility Genes.
    Kurian AW; Ward KC; Abrahamse P; Hamilton AS; Katz SJ
    JNCI Cancer Spectr; 2021 Feb; 5(1):. PubMed ID: 33426465
    [TBL] [Abstract][Full Text] [Related]  

  • 9. BRCA1, BRCA2 and PALB2 mutations and CHEK2 c.1100delC in different South African ethnic groups diagnosed with premenopausal and/or triple negative breast cancer.
    Francies FZ; Wainstein T; De Leeneer K; Cairns A; Murdoch M; Nietz S; Cubasch H; Poppe B; Van Maerken T; Crombez B; Coene I; Kerr R; Slabbert JP; Vral A; Krause A; Baeyens A; Claes KB
    BMC Cancer; 2015 Nov; 15():912. PubMed ID: 26577449
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Breast Cancer Family History and Contralateral Breast Cancer Risk in Young Women: An Update From the Women's Environmental Cancer and Radiation Epidemiology Study.
    Reiner AS; Sisti J; John EM; Lynch CF; Brooks JD; Mellemkjær L; Boice JD; Knight JA; Concannon P; Capanu M; Tischkowitz M; Robson M; Liang X; Woods M; Conti DV; Duggan D; Shore R; Stram DO; Thomas DC; Malone KE; Bernstein L; ; Bernstein JL
    J Clin Oncol; 2018 May; 36(15):1513-1520. PubMed ID: 29620998
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Frequency of pathogenic germline variants in BRCA1, BRCA2, PALB2, CHEK2 and TP53 in ductal carcinoma in situ diagnosed in women under the age of 50 years.
    Petridis C; Arora I; Shah V; Megalios A; Moss C; Mera A; Clifford A; Gillett C; Pinder SE; Tomlinson I; Roylance R; Simpson MA; Sawyer EJ
    Breast Cancer Res; 2019 May; 21(1):58. PubMed ID: 31060593
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Incorporating truncating variants in PALB2, CHEK2, and ATM into the BOADICEA breast cancer risk model.
    Lee AJ; Cunningham AP; Tischkowitz M; Simard J; Pharoah PD; Easton DF; Antoniou AC
    Genet Med; 2016 Dec; 18(12):1190-1198. PubMed ID: 27464310
    [TBL] [Abstract][Full Text] [Related]  

  • 13. EUS-based Pancreatic Cancer Surveillance in
    Katona BW; Long JM; Ahmad NA; Attalla S; Bradbury AR; Carpenter EL; Clark DF; Constantino G; Das KK; Domchek SM; Dudzik C; Ebrahimzadeh J; Ginsberg GG; Heiman J; Kochman ML; Maxwell KN; McKenna DB; Powers J; Shah PD; Wangensteen KJ; Rustgi AK
    Cancer Prev Res (Phila); 2021 Nov; 14(11):1033-1040. PubMed ID: 34341011
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A study of over 35,000 women with breast cancer tested with a 25-gene panel of hereditary cancer genes.
    Buys SS; Sandbach JF; Gammon A; Patel G; Kidd J; Brown KL; Sharma L; Saam J; Lancaster J; Daly MB
    Cancer; 2017 May; 123(10):1721-1730. PubMed ID: 28085182
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Screening for BRCA1, BRCA2, CHEK2, PALB2, BRIP1, RAD50, and CDH1 mutations in high-risk Finnish BRCA1/2-founder mutation-negative breast and/or ovarian cancer individuals.
    Kuusisto KM; Bebel A; Vihinen M; Schleutker J; Sallinen SL
    Breast Cancer Res; 2011 Feb; 13(1):R20. PubMed ID: 21356067
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Associations Between Cancer Predisposition Testing Panel Genes and Breast Cancer.
    Couch FJ; Shimelis H; Hu C; Hart SN; Polley EC; Na J; Hallberg E; Moore R; Thomas A; Lilyquist J; Feng B; McFarland R; Pesaran T; Huether R; LaDuca H; Chao EC; Goldgar DE; Dolinsky JS
    JAMA Oncol; 2017 Sep; 3(9):1190-1196. PubMed ID: 28418444
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Men with metastatic prostate cancer carrying a pathogenic germline variant in breast cancer genes: disclosure of genetic test results to relatives.
    Vlaming M; Ausems MGEM; Schijven G; van Oort IM; Kets CM; Komdeur FL; van der Kolk LE; Oldenburg RA; Sijmons RH; Kiemeney LALM; Bleiker EMA
    Fam Cancer; 2024 Jun; 23(2):165-175. PubMed ID: 38722431
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Detection of pathogenic variants in breast cancer susceptibility genes in bilateral breast cancer.
    Evans DG; Burghel GJ; Schlecht H; Harkness EF; Gandhi A; Howell SJ; Howell A; Forde C; Lalloo F; Newman WG; Smith MJ; Woodward ER
    J Med Genet; 2023 Oct; 60(10):974-979. PubMed ID: 37055167
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The impact of coding germline variants on contralateral breast cancer risk and survival.
    Morra A; Mavaddat N; Muranen TA; Ahearn TU; Allen J; Andrulis IL; Auvinen P; Becher H; Behrens S; Blomqvist C; Bojesen SE; Bolla MK; Brauch H; Camp NJ; Carvalho S; Castelao JE; Cessna MH; Chang-Claude J; Chenevix-Trench G; ; Czene K; Decker B; Dennis J; Dörk T; Dorling L; Dunning AM; Ekici AB; Eriksson M; Evans DG; Fasching PA; Figueroa JD; Flyger H; Gago-Dominguez M; García-Closas M; Geurts-Giele WRR; Giles GG; Guénel P; Gündert M; Hahnen E; Hall P; Hamann U; Harrington PA; He W; Heikkilä P; Hooning MJ; Hoppe R; Howell A; Humphreys K; ; Jakubowska A; Jung AY; Keeman R; Kristensen VN; Lubiński J; Mannermaa A; Manoochehri M; Manoukian S; Margolin S; Mavroudis D; Milne RL; Mulligan AM; Newman WG; Park-Simon TW; Peterlongo P; Pharoah PDP; Rhenius V; Saloustros E; Sawyer EJ; Schmutzler RK; Shah M; Spurdle AB; Tomlinson I; Truong T; van Veen EM; Vreeswijk MPG; Wang Q; Wendt C; Yang XR; Nevanlinna H; Devilee P; Easton DF; Schmidt MK
    Am J Hum Genet; 2023 Mar; 110(3):475-486. PubMed ID: 36827971
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Comparison of BRCA versus non-BRCA germline mutations and associated somatic mutation profiles in patients with unselected breast cancer.
    Chen B; Zhang G; Li X; Ren C; Wang Y; Li K; Mok H; Cao L; Wen L; Jia M; Li C; Guo L; Wei G; Lin J; Li Y; Zhang Y; Han-Zhang H; Liu J; Lizaso A; Liao N
    Aging (Albany NY); 2020 Feb; 12(4):3140-3155. PubMed ID: 32091409
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 18.